Saturday, November 21, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Novo Nordisk Expands Oral Wegovy to UK and New Liver Indication, Implant Study on Horizon

SiterGedge by SiterGedge
July 7, 2026
in Analysis, European Markets, Pharma & Biotech
0
Novo Nordisk Stock
0
SHARES
89
VIEWS
Share on FacebookShare on Twitter

Novo Nordisk is extending its oral Wegovy franchise across multiple fronts simultaneously, with a UK launch, a fresh liver fibrosis approval, and surging US prescription numbers all converging to reinforce the stock’s recent recovery. A hefty buyback programme and upward analyst revisions have added further ballast, though the shares still sit well below their peak.

The Danish drugmaker’s tablet version of semaglutide is now available to private patients in Britain, priced at £69 for a starter pack and £189 for a monthly supply at the highest dose. National Health Service coverage has not yet been granted, but clinical data underpinning the rollout showed weight loss of up to 17% over 52 weeks. At the same time, UK regulators cleared the same active ingredient for advanced liver fibrosis, giving physicians a second therapeutic avenue.

Across the Atlantic, the oral formulation has already generated more than 3 million prescriptions in just five months, the majority from first-time users of the therapy. Demand is poised to accelerate further when the US Medicare “Bridge” programme takes effect on Wednesday, capping monthly out-of-pocket costs for seniors at $50. Novo Nordisk had raised its 2026 revenue guidance earlier in anticipation of the expanded access.

Beyond the immediate pill push, the company is laying groundwork for a longer-term shift. A partnership with Vivani Medical is developing a continuous-release implant designed to eliminate daily dosing entirely. The first Phase 1 trial is scheduled to start in mid-2026.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The operational momentum has not gone unnoticed by the analyst community. HSBC lifted its target to DKK 300 while sticking with a Hold rating, and Danske Bank raised its target to DKK 365 with a Buy recommendation. On Wall Street, the average price objective stands at $46.72, within a wide band of $39.56 to $64.19. Meanwhile, Novo Nordisk’s buyback programme — authorising up to DKK 15 billion in repurchases through February 2027 — continues to provide structural support, with over DKK 6 billion already spent.

The B-shares have responded vigorously, climbing roughly 22% over the past month to trade near €44. They have reclaimed the 200-day moving average and sit comfortably above the 50-day line. Still, the relative strength index has edged close to 70, a level that often flags short-term overextension and may temper further near-term gains.

For all the recent progress, the stock remains approximately 29% below the all-time high struck in July 2025, a reminder of the persistent competitive threat from Eli Lilly. The next crucial test arrives with the half-year results, where investors will scrutinise margin trends. If profit figures beat expectations, the rally could still have room to run despite the overbought signals.

Ad

Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from November 21 delivers the answer:

The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 21.

Novo Nordisk: Buy or sell? Read more here...

Tags: Novo Nordisk
SiterGedge

SiterGedge

Related Posts

Siemens Energy Stock
Energy & Oil

Siemens Energy: Nuclear Ambitions Meet Chart Warnings as CEO Urges Crisis Preparedness

September 7, 2026
SAP Stock
Analysis

SAP’s Buyback Machine Grinds On, But the Analyst Chorus Is Turning Sour

September 7, 2026
TKMS Stock
Defense & Aerospace

TKMS Closes the Dolphin Chapter and Courts Fincantieri — But Shareholders Are Still Waiting for the Tide to Turn

September 7, 2026
Next Post
FALLBACK Stock

Lancashire Container Manufacturer Fined £36,000 Over Welding Fume Risks

VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF Stock

Investors Pour €414m into VanEck Dividend ETF as Bank Sector Drama Intensifies

Volkswagen Stock

Volkswagen's €7.4bn Engine Sale and an Analyst's Upgrade: A Tale of Two Signals

Recommended

WM stock news

Spire Wealth Management Shows Confidence in Churchill Downs Incorporated with New Acquisition and Bet on Future Growth

3 years ago
Chevron Stock

Chevron Shares Surge Amid Global Oil Supply Disruption

8 months ago
Q2 Holdings Stock

Inclusion in S&P SmallCap 600 Index Ignites Q2 Holdings Stock Rally

1 year ago
REV Stock

REV Group Shares Hit Record High Amid Political Scrutiny

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

At 5.15%, the 10-Year Treasury Picks the Winners

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

Trending

CrowdStrike Stock
Newsletter

93% of Stocks Fall as CrowdStrike Courts Zscaler

by Stephanie Dugan
November 21, 2026
0

Dear readers, The question heading into Friday was whether Anthropic would hold its $83 offer price. It...

Nvidia Stock

Anthropic Lists at a Premium, but the Sell-Off Keeps Going

November 20, 2026
Bitcoin Stock

Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

November 19, 2026
Nvidia Stock

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

November 18, 2026
Home Depot Stock

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

November 17, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • 93% of Stocks Fall as CrowdStrike Courts Zscaler
  • Anthropic Lists at a Premium, but the Sell-Off Keeps Going
  • Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com